Caribou Biosciences, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M | $12.4M | $5.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $109.4M | $130.2M | $112.1M | $82.2M | $52.3M | $34.4M | $23.6M |
| SG&A Expense | — | $37.9M | $46.5M | $38.5M | $38.0M | $24.3M | $14.1M | $16.5M |
| Operating Income | — | $-148.3M | $-166.6M | $-116.1M | $-106.4M | $-67.0M | $-36.1M | $-34.3M |
| Operating Margin | — | -1,329.4% | -1,667.2% | -336.6% | -768.2% | -697.8% | -292.2% | -592.7% |
| Interest Expense | — | — | — | — | — | $8.0K | $20.0K | $4.0K |
| Pretax Income | — | $-148.7M | $-149.1M | $-101.9M | $-99.4M | $-66.6M | $-36.1M | $-31.0M |
| Income Tax Expense | — | $-550.0K | $-9.0K | $193.0K | $70.0K | $321.0K | $-1.8M | $-7.5M |
| Net Income | — | $-148.1M | $-149.1M | $-102.1M | $-99.4M | $-66.9M | $-34.3M | $-23.4M |
| Net Margin | — | -1,327.4% | -1,491.9% | -296.1% | -717.8% | -697.3% | -277.6% | -404.8% |
| EPS (Basic) | — | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 | $-4.01 | $-2.80 |
| EPS (Diluted) | — | $-1.59 | $-1.65 | $-1.38 | $-1.64 | $-2.11 | $-4.01 | $-2.80 |
| Shares Outstanding (Basic) | 96.6M | 93.4M | 90.3M | 73.8M | 60.8M | 31.7M | 9.7M | — |
| Shares Outstanding (Diluted) | 96.6M | 93.4M | 90.3M | 73.8M | 60.8M | 31.7M | 9.7M | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |